Российское диализное общество

Просмотр статьи

<< Вернуться к списку статей журнала

Том 2 №3 2000 год - Нефрология и диализ

Роль паратиреоидного гормона и витамина D в развитии кардиоваскулярных нарушений при хронической почечной недостаточности (Обзор литературы)


Волгина Г.В. Перепеченых Ю.В.

Аннотация: Кардиоваскулярные нарушения (КВН) являются главной причиной смерти больных, страдающих терминальной хронической почечной недостаточностью (ТХПН) и получающих лечение гемо- или перитонеальным диализом [3, 11, 19, 64, 67, 75-77, 86, 91]. Частота КВН при ТХПН, по данным Европейской ассоциации диализа и трансплантации (ЭДТА), Почечного реестра США (USRDS) и Национального института статистики здоровья (NCHS), составляет 40-50%, а ежегодная смертность диализных больных вследствие этой патологии равна 7-9,5%, что в двадцать-тридцать раз превышает сердечно-сосудистую летальность в общей популяции [11, 64, 75-77, 86]. Таким образом, актуальность проблемы сердечно-сосудистой патологии при хронической почечной недостаточности (ХПН) неоспорима, и эта категория больных представляет группу «высочайшего риска» развития КВН [75, 91, 117].

Весь текст



Ключевые слова: ХПН, кардиоваскулярные нарушения, ПТГ, витамин D3, кальциево-фосфорный обмен

Список литературы:
  1. Барабанова Т.А., Пенчук Н.А. Миокард, паратиреоидный гормон и хроническая почечная недостаточность. Нефрология, 1998; 2; 2: 88-94.
  2. Общий курс физиологии человека и животных. Под ред. А.Д. Ноздрачева. М.: Высшая школа, 1991; 2; 192-195.
  3. Akmal M., Kasim S.E., Soliman S.E., Massry S.G. Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure. Kidney Int. 1990; 37: 854-858.
  4. Akmal S.U., Massry S.G., Goldstcin D.A. et al. Role of parathyroid hormone in the glucose intolerance of chronic renal failure. J Clin Invest 1985; 75: 1037-1044.
  5. Amann K., Ritz E., Wiest G., Klaus G., Mall G. A role of parathyroid hormone for activation of cardiac fibroblast in uremia. J Amer Soc Nephrol 1994; 4(10): 1814-1819.
  6. Amann K., Torning J., Fiechtenmacher C. et al. Blood-pressure-indepedent wall thickening of intramyocardial arterioles in experimental uraemia-evidence for a permissive action of PTH. Nephrol Dial Transplant 1995; 10: 2043-2048.
  7. Aronow W.S., Schwartz K.S., Koenisberg M. Correlation calcium and phosphorus, diabetes mellitus, aortic valve stenosis and history of systemic hypertension with presence or absence of mitral annular calcium in person older than 62 years in long-term health care facility. Am J Cardiol 1987; 59: 381-382.
  8. Aronow W.S., Schwartz K.S., Koenisberg M. Correlation of atrial fibrillation with presence of mitral annular calcium in 604 person older than 60 years. Am J Cardiol 1987; 59: 1213-1214.
  9. Auwerx J., Bouillon R., Kesteloot M. Relation between 25-hydroxyvitamin D3, apolipoprotein A-1, and high density lipoprotein cholesterol. Arterioscler Thromb 1992; 12: 671-674.
  10. Baczynski R., Massry S.G., Kohan K. et al. Effect of parathyroid hormone on myocardial energy metabolism in the rat. Kidney Int 27: 1985; 718-725.
  11. Bailey G.L., Hampers C.L., Merril J.P. Reversible cardiomyopathy in uremia. Trans Am Soc Artif Intern Organs 1967; 13: 263-270.
  12. Bogin E., Levi J., Massry S.G. Effects of parathyroid hormone on oxidative phosphorylation on heart mitochondria. Miner Electrolite Metab 1982; 7: 151-156.
  13. Bogin E., Massry S.G., Harray I. Effect of parathyroid hormone on rat heart cells. J Clin Invest Med 1981; 67: 1215-1227.
  14. Bostrom K., Watson K.E., Horn S. et al. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 1993; 91: 1800-1809.
  15. Braun J., Oldendorf M., Mochage W. et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996; 27: 394-401.
  16. Brown E.M., Pollak M., Riccardi D., Hebert S.C. Cloning and characterization of an extracellular Ca-sensing receptor from parathyroid and kidney: new insights into the physiology and pathophysiology of calcium metabolism. Nephrol Dial Transplant 1994; 9: 1703-1706.
  17. Brown A.J., Ritter C., Fineh J., Slatopolsky E. Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: role of dietary phosphate. Kidney Int 1999; 55: 1284-1292.
  18. Burnside J.W., Desanctis R.W. Bacterial endocarditis on calcification of the mitral anulus fibrosus. Ann Intern Med 1972; 76: 615-618.
  19. Burton P.R., Walls J. Selection-adjusted comparison of life-expectancy of patients on continuous ambulatory peritoneal dialysis, hemodialysis, and renal transplantation. Lancet 1987; 1: 1115-1119.
  20. Chen S., Wu J., Hsieh J.C. et al. Supression of ANP gene transcription by liganded vitamin D receptor: involvement of specific receptor domains. Hypertension 1998; 31: 1338-1342.
  21. Chen Y.F., Jang R.H., Meng Q.C. et al. Sodium-proton (Na+/H+) exchange inhibition increases blood pressure in spontaneously hypertensive rat. Am J Med Sci 1994; 308: 145-151.
  22. Coratelli P., Petrarulo F., Buongiorno E. et al. Imprevement in left ventricular function during treatment of hemodialysis patients with 25-OH D3. Contrib Nephrol 1984; 41: 433-437.
  23. Coratelli P., Buongiorno E., Petrarulo F. et al. Pathogenetic aspects of uremic cardiomyopathy. Miner Electrolyte Metab 1989; 15: 1-8.
  24. Crozier I.G., Richads A.M., Ikram H., Nicholls M.D. The renin-angiotensin system, ACE-inhibitors and cardiac structure. The renin-angiotensin system. Eds. I.R.S. Robertson, M.G. Nicholls. London-New-Iork 1993; 2: 94: 94.1-94.9.
  25. De Fronzo R.A., Alvestrand A., Smith D. et al. Insulin resistence in uremia/ J Clin Invest 1981; 67: 563-568.
  26. Demer L.L. Lipid hypotesis of cardiovascular calcification. Circulation 1997; 95: 297-298.
  27. Derey G., Maistre G., Basset J.Y. et al. Plasma levels of atrial natriuretic peptide in chronically dialyzed patients. 1988 Kidney Int 34 (suppl. 25): 86-88.
  28. Dominiczak A.F., Lyall F., Morton J.J. et al. Blood pressure, left ventricular mass and intracellular calcium in primary hyperparathyroidism. 1990; Clin Sci 78: 127-132, 1990.
  29. Drau V.J. The role of mechanical and humoral factors in growth regulation of vascular smooth muscle and cardiac myocytes. Curr Opin Nephrol Hypertens 1993; 2: 27-32.
  30. Duprez D., Bauwens F., De Buyzere M. et al. Relationship between parathyroid hormone and left ventricular mass in moderate essential hypertention. J Hypertens 1991; 9 (suppl. 6): 116-117.
  31. Ejerblad S., Eriksson I., Johansson H. Uraemic arterial disease: an experimental study with special reference to the effect of parathyroidectomy. Scand J Urol Nephrol 1979; 13: 161-169.
  32. Fensenfeld A.J., Llach F. Parathyroid gland function in chronic renal failure. Kidney Int 1993; 43: 771-789.
  33. Fernandez-Reyes M.J., Auxiladora Bajo M., Robles P. et al. Mitral annular calcification in CAPD patients with a low degree of HPT. An analysis of other possible risk factors. Nephrol Dial Transplant 1995; 10: 2090-2095.
  34. Fliser D., Franek E., Fode P. et al. Subacute infusion of physiologic doses of parathyroid hormone raises blood pressure in humans. Nephrol Dial Transplant 1997; 12: 933-938.
  35. Foley R.N., Parfrey P.S., Harnett J.D. et al. Clinical and echocardiographic disease in end-stage renal disease: prevalens, associations and prognosis. 1995; Kidney Int 47: 186-192.
  36. Foley R.N., Parfrey P.S., Harnett J.D. et al. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 1995; 5: 2024-2031.
  37. Forman M.B., Virmani R., Robertson R.M., Stone W.J. Mitral annular calcification in chronic renal failure. 1984; Chest 85: 367-371.
  38. Fullkerson P.K., Beaver B.M., Auseon J.C., Graber H.L. Calcification of the mitral annulus: etiology, clinical associations, complications and therapy. Am J Med 1079; 66: 967-977.
  39. Gabor G.E., Mohr B.D., Goel P.C., Cohen B. Echocardiographic and clinical spectrum of mitral annular calcification. Am J Cardiol 1976; 38: 836-842.
  40. Ganguly P.K. Catecholamined and cardiovascular disorders: pathophysiologic considerations. Am Heart J 1989; 118: 868-872.
  41. Ganten D., Luft F.C., Kurokawa K.K. Hormones, autocoids, neurotransmitters and growth factors. Curr Opin Nephrol Hypertens 1993; 2: 1-4.
  42. Geiger H., Bahner U., Meisner M. et al. Parathyroid hormone modulates the release of atrial natriuretic peptide during acute volume expansion. Am J Nephrol 1992; 12: 259-264.
  43. Geiger H., Bachner U., Palkowits M. et al. Is the effect of calcium diet or parathyroidectomy on the development of hypertension in spontaneous hypertensive rats mediated by atrial natriuremic peptide? Kidney Int1988; 34: 93-97.
  44. Gokal R., Jakubowski C., King J. et al. Outcome in patients on continuous ambulatory peritoneal dialysis and hemodialysis: 4-years analysis of o prospective multicentre stu1987; dy. Lancet 14: 1105-1109.
  45. Ha S.K., Park H.S., Kim S.U. et al. Prevalence and patterns of left ventricular hypertrophy in patients with predialysis chronic renal failure. J Korean Med Sci 1998; 13(5), 488-494.
  46. Hara S., Ubara Y., Arisono K. et al. Relation between parathyroid hormone and cardiac function in long-term hemodialysis patients. Miner Electrolyte Metab1995; 21: 72-76.
  47. Harnett J.D., Parfrey P.S., Griffiths S.M. et al. Left ventricular hypertrophy in end-stage disease. Nephron 1988; 48; 107-115.
  48. Harris D.C.H., Hammond W.S., Burke T.J., Schrier R.W. Verapamil protects against progression of experimental chronic renal failure. Kidney Int 1987; 31: 41-46.
  49. Helwig J.J., Musso M.J., Judes C., Nickols G.A. Parathyroid hormone and calcium: interaction in the control of renin secretion in the isolated, nonfiltering rat kidney. Endocrinology 1991; 129: 1233-1242.
  50. Hsu C.H. Are we mismanaging calcium and phosphate metabolism in renal failure. Am J Kidney Dis 1997; 29: 641-649.
  51. Isales C.M., Barrett P.Q., Brines M., Bollag W., Rasmussen H. Parathyroid hormone modulates angiotensin 11-induced aldosterone secretion from the adrenal glomerular cell. Endocrinology 1991; 129: 489-495.
  52. Jespersen B., Fogo-Andersen N., Brock A. Parathyroidddd hormone in blood pressure and volum homeostasis in healthy subjects, hyperparathyroidism, liver cirrhosis and glomerulonephritis. A possible interaction with angiotention 11 and atrial natriuretic peptide. Scand J Clin Lab Invest 1994; 54: 531-541.
  53. Jespersen B., Petersen E.B., Charles P. et al. Elevated angiotensin 11 and vasopressin in primary hyperparathyroidism. Angitensin 11 infusion studies before and after removal of the parathyroid adenoma. Acta endocrinol 1989; 120: 362-368.
  54. Jurden H. Mitral valve calcification as an index of left ventricular dysfunction in patients with end-stage renal disease on peritoneal dialysis. Chest 1994; 105: 383-388.
  55. Kilav R. PTH gene expression in hypophosphatemic rats.
  56. J Clin Invest (in press)
  57. Klaus G., May T., Hugel U. et al. Parathyroid hormone: prevents 1,25(OH)2D3 induced down-regulation of the vitamin D receptor in grown plate chrondrocytes «in vitro». Kidney Int 1997; 51: 45-51.
  58. Klin M., Smogorzewski M., NiZ. et al. Abnormalites in hepatic lipase in chronic renal failure: role of excess parathyroid hormone. J Clin Invest 1996; 97: 2167-2173.
  59. Kraikinpanitch S., Lindeman R.D., Joenice A.A. et al. Effect of azotemia and myocardial accumulation of calcium/ Miner Electrolyte Metab 1: 12-20, 1978.
  60. Kristal-Boneh E., Froom P., Harari G., Ribac J. Assotiation of calcitriol and blood pressure in normotensive men. Hypertention 1997; 30: 1289-1294.
  61. Kurz P., Monier-Faugere M.C., Bognar B. et al. Abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994; 46: 855-861.
  62. Lacour B., Roullet J-B., Liagre A.M. et al. Serum lipoprotein disturbance in primary and secondary hyperparathyroidism and effect of parathyroidectomy/ Am J Kidney Dis 1986; 8: 422-429.
  63. Lang R.M., Fellner S.K., Neumann A., Bushinsky D.A., Borow K.M. Left ventricular contractility varies directly with blood ionized calcium. Ann Intern Med 1988; 108: 524-529.
  64. Lemmila S., Saha H., Virtanen V., Ala-Houhala I., Pasternack A. Effect of intravenous calcitriol on cardiac systolic and diastolic function in patients on hemodialysis. Am J Nephrol 1998; 18: 404-410.
  65. Levey A.S., Beto J.A., Coronado B.E. et al. Controling the epidemic of cardiovascular disease in chronic renal disease: What do we Know? What do we need to learn? Where do we go from Here? Am J Kidney Dis 1998; 32: 853-906.
  66. Liang K., Oveisi F., Vasiri N.D. Role of secondary hyperparathyroidism in the genesis of hypertriglyceridemia and VLDL receptor deficiency in chronic renal failure. Kidney Int 1998; 53: 626-630.
  67. Lind L., Hanni A., Lithell H. et al. Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am J Hypertens 1995; 8: 894-901.
  68. Linder A., Charra B., Sherrard L., Scribner B.M. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697-701.
  69. Llach F., Massry S.G., Singer F.R. Skeletal resistence of endogenus PTH in patients with early renal failure. A possible cause of secondary hyperparathyroidism. J Clin Endocrinol Metab 1975; 44: 1054-1058.
  70. London G.M., Drueke T.B. Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 1997; 51: 1678-1695.
  71. London G.M., Vernerejoul M., Fabiani F. et al. Secondory hyperparathyroidism and cardiac hypertrophy in hemodialysis patients. Kidney Int. 1987; 32: 900-907.
  72. London G.M., Zins B., Pannior B. et al. Vascular changes in hemodialysis patients in response to rHuEPO. Kidney Int 1989; 36: 878-882.
  73. Lopex-Hilker S., Dusso A.S., Rapp N.S. et al. Phosphorus restriction reverses secondary hyperparathyroidism independent of changes in Ca2+ and calcitriol. Am J Physiol 1990; 259: 432-437.
  74. Low I., Grutzmacher P., Bermann M., Scheppe W. Echocardiographic findings in patient on maintenance hemodialysis patients substituted with rHuEPO. Clin Nephrol 1989; 31: 26-30.
  75. Maccarthy E.P., Jamashita W., Hsu A., Oor B.S. 1,25-Dihydroxyvitamin D3 and rat vascular smooth muscle growth. Hypertention 1997; 13: 954-959.
  76. Maiorca R., Canearini G.C., Brunori G. et al. Morbidity and mortality of CAPD and hemodialysis. Kidney Int 43(suppl.40): 1993; 4-15.
  77. Maiorca R., Vonesh E.F., Cancarini G.C. et al. A six-year comparison of patients and technique survivals on CAPD and HD. Kidney Int 1988; 34: 518-524.
  78. Maiorca R., Vonesh E.F., Cavalli P.L. et al. A multicenter selection - adjusted comparison of patients and technique survivals on CAPD and hemodialysis. Perit Dial Int 1991; 11: 118-127.
  79. Mak R.N.K. 1,25 Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int 1998; 53: 1353-1357.
  80. Mall G., Rambausck M., Neumeister A. et al. Myocardial interstitial fibrosis in experimental uremia-implications for cardiac compliance. Kidney Int 1988; 33: 804-811.
  81. Massimetti C., Botti M., Capezzuto A. et al. Effects of pharmacological correction of secondary hyperparathyroidism (HPT 11) on cardiac function in haemodialysis patients. Nephrol Dial Transplant 1994; 9: 911-912.
  82. Massry S.G., Smogorzewski M. The mechanisms responsible for the PTH induced rise in cytosolic calcium in various cells are not uniform. Miner Electrolyte Metab 1982; 7: 151-156.
  83. Mazzaferro S., Coen G., Bandini S. et al. Role of ageing, chronic renal failure and dialysis in the calcification of mitral annulus. Nephrol Dial Transplant 1993; 8: 335-340.
  84. Milliner D.S., Zinsmeister A.R., Lieberman E., Landing B. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 1990; 38: 931-936.
  85. Mitsuhashi T., Morris R.C., Ives H.E. 1,25-Dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells. J Clin Invest 1991; 87: 1889-1895.
  86. Nair C.K., Thomson W., Ryschon K. et al. Long-term follow-up of patients with echocardiographically detected mitral annular calcium and comparison with age-and-sex-matched control subjects. Am J Cardiol 1987; 59: 1213-1214.
  87. National Kidney Foundation Task Force on cardiovascular disease: controlling the epidemic of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 (suppl. 3): 1-199.
  88. Naveh-Many T., Marx R., Keshet E. et al. Regulation of 1,25(OH)2D3 receptor gene expression by 1,25(OH)2D3 in the parathyreoid in vivo. J Clin Invest 1990; 86: 1968-1975.
  89. Nyby M.B., Hino T., Berger M.E. et al. Desensitization of vascular tissue to parathyroid hormone and parathyroid hormone-related protein. Endocrinology 1995; 136: 2497-2504.
  90. Ongino K., Burkhoff D., Bole Zikian J.P. The hemodynamic basis for the effects of PTH and PTHrP. Endocrinology 1995; 136: 3024-3030.
  91. Pang P.K., Benishin C.G., Lewanczuk R.Z. Parathyroid hypertensive factor, a circulating factor in animal and human hypertention. Am J Hypertention 1991; 4: 472-477.
  92. Parfrey P.S., Harnett J.D., Barre P.E. The natural history of myocardial disease in dialysis patients. J Am Soc Nephrol 1991; 2: 2-12.
  93. Park C.W., Oh Y.S., Shin Y.S. et al. Intravenous calcitriol regress myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Amer J Kidney Dis 1999; 33(1), 73-81.
  94. Perna A.F., Smogorzewski M., Massry S.G. Verapamil reverse PTH - or CRF-induced abnormal fatty acid oxidation in muscle. Kidney Int 1988; 34: 774-778.
  95. Pillai S., Birlke D.D., Su M.J. et al. 1,25-Dihydroxyvitamin D3 upregulates the phosphatidyl-inositol signalling pathway in human keratinocytes by increasing phospholipase C level. J Clin Invest 1995; 96: 602-607.
  96. Pizarelli F., Fabrizi F., Postorino M. et al. Parathyroidectomy and blood pressure in hemodialysis patients. Nephron 1993; 63; 384-389.
  97. Portalle A.A. Effects of dietary phosphorus on circulations of 1,25 dihydroxyvitamin D and immunoreactive parathyroid hormone in children with insufficiency. J Clim Invest 1984; 73: 1580-1589.
  98. Qing D.P., Ding H., Vadgama J. et al. Elevate myocardial cytosolic calcium impairs insulin-like growth factor-1 stimulated protein syntesis in CRF. J Am Soc Nephrol 1999; 10: 84-92.
  99. Rambausek M., Ritz E., Mall G. et al. Myocardial hypertrophy in rats with renal insufficiency. Kidney Int 1985; 28: 775-782.
  100. Ritz E., Stefanski A., Rambausek M. The role of the parathyroid glands in the uremic syndrome. Am J Kidney Dis 1995; 26(5), 808-813.
  101. Roca Cusachs A., Di Pette D.J., Nickols G.A. Regional and systemic haemodinamic effects of PTH-rP: preservation of cardiac and coronary and renal flow with reduced blood pressure. J Pharmacol Exp Ther 1991; 90: 72-78.
  102. Rostand S.G., Sanders P.C., Rutsky E.A. Cardiac calcification in uremia. Contrib Nephrol 1993; 106: 26-29.
  103. Sato S., Ohta M., Kawaguchi Y. et al. Effects parathyroidectomy on left ventricular mass in patients with hyperparathyroidism. Miner Electrolyte Metab 1995; 21: 67-71.
  104. Schleiffer R. Involvement of PTH in genetic models of hypertention J Endocrin Investig 1992; 15: 87-95.
  105. Schleiffer R., Pernot F., Jonest R. Endothellium is a target organ of parathyroid secrecions in genetic hypertensive rats. Horm Metab Res 1995; 27: 16-18.
  106. Schluter K.D., Piper H.M. Trophic effects of catecholamines and parathyroid hormone on adult ventricular cardiomyocytes. Am J Physiol 1992; 263: 1739-1746.
  107. Shane E., Mancini D., Aaronson K. et al. Bone mass, vitamin D defficiency and hyperparathyroidism in congestive heart failure. Am J Med 1997; 103: 197-207.
  108. Silberberg J.S., Rahal D.P., Patton R., Sniderman A.D. Role of anemia in the pathogenesis of LVH in ESRD. Am J Cardiol 1989; 64: 222-224.
  109. Silver J., Naweh-Many T., Mayer H. et al. Regulation by vitamin D metabolites of parathyroid gene transcription in vivo in rat. J Clin Invest 1986; 78: 1296-1301.
  110. Smogorzewski M. PTH, chronic renal failure and myocardium. Miner Electrol Metab 1995; 21: 55-62.
  111. Smogorzewski M., Massry S.G. Uremic cardiomyopathy role of parathyroid hormone. Kidney Int (suppl.) 1997; 62, 12-14.
  112. Smogorzewski M., Zayed M., Zhang Y. Parathyroid hormone increases cytosolic calcium concentration in adult rat cardiac myocytes. Amer J Physiol 1993; 264: 2006-2012.
  113. Somers V.K., Anderson E.A., Mark A.L. Sympathetic neural mechanisms in human hypertension. Curr Opin Nephrol Hypertens 1993; 2: 96-105.
  114. Stefenelli T., Mayr H., Bergler-Klein J. et al. Primary hyperparathyroidism: incidence of cardiac abnormalities and partial reversibility after successful parathyroidectomy. Am J Med 1993; 95: 197-202.
  115. Stephen G., Rostand S.G., Tilman B. Parathyroid hormone, vitamin D and cardiovascular disease in chronic renal failure. Kidney Int 1999; 56: 383-392.
  116. Symons G., Fortune F., Greenbaum R.A., Dandona P. Cardiac hypertrophy, hypertrophic cardiomyopathy, and hyperparathyroidism - an association. Br Heart J 1985; 54: 539-542.
  117. Terman D.S., Alfrey A.C., hammond W.S. et al. Cardiac calcification in uremia: a clinical, biochemical and pathological study. Am J Med 1971; 50: 744-755.
  118. Thuraisingham R.C., Tucker B., Lipkin G.W. et al. Left ventricular hypertrophy in early renal failure. RA-BAPN, oct., 859, 1993 (abstract).
  119. Gi H., Fukagawa M., Jamato H. et al. Prevention of enhanced parathyroids hormone secretion, sinthesis and hyperplasia by mild dietary phosphorus restriction in early chronic renal failure in rats: possible direct role of phosphorus. Nephron (in press).
  120. Tian J., Smogorzewski M., Kedes L., Massry S.G. PTH - PTHrP receptors mRNA in downregulated in chronic renal failure. Am J Nephrol 1994; 14: 41-46.
  121. Virtanen V.K., Saha H.H.T., Groundsrom K.W.E., Seppala E.S., Pasternack A.I. Caicium infution and left ventricular diastolic function in patients with chronic renal failure. Nephrol Dial Transplant 1998; 13: 384-388.
  122. Waller B.F., Roberts W.C. Cardiovascular disease in the very eldery. Am J Cardiol 1983; 51: 403-421.
  123. Watson K.E., Abrolat M.L., Malone L.L. et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 1997; 96: 1755-1760.
  124. Weishaar R.E., Kim S.M., Saunders D.E., Simpson R.U. Involvement of vitamin D with cardiovascular function: effects on physical and morphological properties. A J Physiol 1990; 258: 134-142.
  125. Wu J., Garami M., Cao L., Gardner D.G. 1,25(OH)2D3 suppresses expression and secretion of atrial natriuretic peptide from cardiac myocytes. Am J Physiol 1995; 268: 1108-1113.
  126. Zahavi I., Chagnac A., Djaldetti M., Levy J. Effect of verapamil on uremic myocardial disease in the rat. J Submicrosc Cytc 1985; 17: 637-644.

Другие статьи по теме


Навигация по статьям
Разделы журнала
Наиболее читаемые статьи
Журнал "Нефрология и диализ"